Kidney Allograft Dysfunction Diagnostic Workup

Authored by Sourabh Sharma, published on 2026-11-12 16:23:37.0

Confirm Dysfunction Against Baseline Creatinine/eGFR, Urine Output, and Proteinuria
- Determine Time Since Transplantation
  - 0–7 Days: Prioritize DGF, ATI, Vascular, Haemodynamic, Urological, and Hyperacute/Early ABMR Causes
    - Maintain Full Differential Regardless of Timing
      - Assess Volume, Sepsis, Cardiac Function, Adherence, Drug Interactions, and CNI Levels
        
        Obtain Urinalysis, Protein Quantification, DSA, BK/CMV PCR, Haemolysis Studies, Cultures, and Allograft Doppler
        
        Is an Immediate Correctable Cause Identified?
        
        Urgently Confirm and Escalate Vascular or Urological Complication
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Confirm and Manage BK, CMV, Pyelonephritis, or Other Infection
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Correct Haemodynamic Cause and Address CNI Toxicity or Drug Interaction
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Manage Immediate Cause While Proceeding Concurrently to Allograft Biopsy
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Urgently Confirm and Escalate Vascular or Urological Complication
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
  - 8 Days–12 Months: Prioritize Rejection, CNI Toxicity, BK/CMV, ATI, Glomerular, Urological, and Vascular Causes
    - Maintain Full Differential Regardless of Timing
      - Assess Volume, Sepsis, Cardiac Function, Adherence, Drug Interactions, and CNI Levels
        
        Obtain Urinalysis, Protein Quantification, DSA, BK/CMV PCR, Haemolysis Studies, Cultures, and Allograft Doppler
        
        Is an Immediate Correctable Cause Identified?
        
        Urgently Confirm and Escalate Vascular or Urological Complication
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Confirm and Manage BK, CMV, Pyelonephritis, or Other Infection
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Correct Haemodynamic Cause and Address CNI Toxicity or Drug Interaction
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Manage Immediate Cause While Proceeding Concurrently to Allograft Biopsy
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Urgently Confirm and Escalate Vascular or Urological Complication
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
  - >12 Months: Prioritize Chronic Rejection, Transplant Glomerulopathy, Glomerular Disease, CNI Toxicity, BK, IF/TA, and Structural Causes
    - Maintain Full Differential Regardless of Timing
      - Assess Volume, Sepsis, Cardiac Function, Adherence, Drug Interactions, and CNI Levels
        
        Obtain Urinalysis, Protein Quantification, DSA, BK/CMV PCR, Haemolysis Studies, Cultures, and Allograft Doppler
        
        Is an Immediate Correctable Cause Identified?
        
        Urgently Confirm and Escalate Vascular or Urological Complication
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Confirm and Manage BK, CMV, Pyelonephritis, or Other Infection
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Correct Haemodynamic Cause and Address CNI Toxicity or Drug Interaction
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Manage Immediate Cause While Proceeding Concurrently to Allograft Biopsy
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
        
        Urgently Confirm and Escalate Vascular or Urological Complication
        
        Does Dysfunction or Proteinuria Persist After Initial Management?
        
        Resume Cause-Directed Surveillance
        
        Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
        
        Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings
- Urgently Confirm and Escalate Vascular or Urological Complication
  - Does Dysfunction or Proteinuria Persist After Initial Management?
    - Resume Cause-Directed Surveillance
    - Promptly Biopsy Unexplained Dysfunction, Suspected Rejection, DSA, or New Proteinuria
      - Interpret Biopsy by Current Banff With C4d, DSA, SV40, IF/EM, and Molecular Diagnostics as Available
        
        Initiate TCMR, ABMR, or Chronic Active Rejection Pathway
        
        Initiate BK, CMV, or Pyelonephritis Management Pathway
        
        Initiate Recurrent or De Novo Glomerular Disease Pathway
        
        Address CNI Toxicity or TMA Driver
        
        Manage Transplant Glomerulopathy, IF/TA, or Chronic Injury
        
        Manage ATI or DGF; Reassess Nondiagnostic or Discordant Findings

tos privacy